EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY-NC 4.0

Persistent CD8+ T-cell activation (HLA-DR/CD38) as an immunological marker in antiretroviral-treated human immunodeficiency virus-1 patients: A cross-sectional study

Filiz Kibar iD, Salih Çetiner, Ayşe Seza İnal, Alev Çetin Duran, Gülşah Seydaoğlu, Ferit Kuşçu, Süheyla Kömür, Akgün Yaman

Journal of International Medical Research · 2026

DOI: 10.1177/03000605261476785 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Journal of International Medical Research, 2026. Verfasst von Filiz Kibar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Faculty of Medicine, Cukurova University, Turkey. Hauptthemen laut MEDLINE: HLA-DR Antigens, CD8-Positive T-Lymphocytes, HIV Infections, Lymphocyte Activation. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To analyze the relationship among CD8+ T-cell activation markers (CD38/human leukocyte antigen–D-related (HLA-DR)), viral load, and CD4+/CD8+ counts in patients with human immunodeficiency virus-1 receiving antiretroviral therapy in Southern Turkey and evaluate their potential as indicators of persistent immune activation.

Methods

Ninety-nine patients receiving antiretroviral therapy were included in this cross-sectional study. Human immunodeficiency virus RNA was quantified using real-time polymerase chain reaction, whereas CD4+, CD8+, and activation markers (CD38, HLA-DR) were analyzed using flow cytometry.

Results

Patients with detectable viral load (viral load ≥20 copies/mL) had significantly higher percentages of CD8+ CD38+, CD8+ HLA-DR+, and dual-positive CD8+ CD38+ HLA-DR+ T-cells than those with suppressed viral load (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HLA-DR AntigensCD8-Positive T-LymphocytesHIV InfectionsLymphocyte ActivationHIV-1ADP-ribosyl Cyclase 1Membrane GlycoproteinsHumansFemaleCross-Sectional StudiesMaleViral LoadAdultMiddle AgedBiomarkersAntiretroviral Therapy, Highly Active

Stichwörter der Autor:innen

CD38CD8HLA-DRHuman immunodeficiency virusantiretroviral therapyflow cytometryimmune activationimmunological marker

Substanzen

HLA-DR AntigensADP-ribosyl Cyclase 1BiomarkersMembrane GlycoproteinsCD38 protein, human

Autor:innen und Institutionen

  • Department of Medical Microbiology, Faculty of Medicine, Cukurova University, Turkey.
  • Hospital Central Laboratory, Faculty of Medicine, Cukurova University, Turkey.
  • Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Cukurova University, Turkey.
  • Department of Biostatistics, Faculty of Medicine, Cukurova University, Turkey.

ORCID-Profile: Filiz Kibar

Zitieren

APA

Kibar, F., Çetiner, S., İnal, A. S., Duran, A. Ç., Seydaoğlu, G., Kuşçu, F., Kömür, S., & Yaman, A. (2026). Persistent CD8+ T-cell activation (HLA-DR/CD38) as an immunological marker in antiretroviral-treated human immunodeficiency virus-1 patients: A cross-sectional study. Journal of International Medical Research. https://doi.org/10.1177/03000605261476785

Vancouver

Kibar F, Çetiner S, İnal AS, Duran AÇ, Seydaoğlu G, Kuşçu F, et al. Persistent CD8+ T-cell activation (HLA-DR/CD38) as an immunological marker in antiretroviral-treated human immunodeficiency virus-1 patients: A cross-sectional study. Journal of International Medical Research. 2026. doi:10.1177/03000605261476785

BibTeX
@article{Kibar2026,
  author = {Kibar, Filiz and Çetiner, Salih and İnal, Ayşe Seza and Duran, Alev Çetin and Seydaoğlu, Gülşah and Kuşçu, Ferit and Kömür, Süheyla and Yaman, Akgün},
  title = {Persistent CD8+ T-cell activation (HLA-DR/CD38) as an immunological marker in antiretroviral-treated human immunodeficiency virus-1 patients: A cross-sectional study},
  journal = {Journal of International Medical Research},
  year = {2026},
  doi = {10.1177/03000605261476785}
}
Kostenlos starten →